ASX-173 - CAS 2748800-08-8

ASX-173 is an orally active asparagine synthetase (ASNS) inhibitor with an IC50 of 0.113 μM and a Ki of 0.4 nM. It enhances the anticancer activity of L-Asparaginase (ASNase) . When combined with ASNase, ASX-173 disrupts nucleotide synthesis and induces cell cycle arrest, apoptosis (apoptosis), and autophagy (autophagy) in leukemia cells. This combination also slows the growth of OCI-AML2 xenograft tumors. ASX-173 is applicable in research on acute lymphoblastic leukemia, acute myeloid leukemia, colorectal cancer, and other cancers.

CDK, ATG, Autophagy, Apoptosis, Akt, PARP, Caspase

Apoptosis, Cell Cycle/Checkpoint, Autophagy, Cytoskeletal Signaling, Proteases/Proteasome, PI3K/Akt/mTOR signaling, DNA Damage/DNA Repair, Chromatin/Epigenetic

2748800-08-8

C28H30FN3O3

475.56

C(NC(C1=CC=CC=C1)C2=CC=CC=C2)(=O)[C@@H]3N(C([C@H](CC)N)=O)C[C@H]([C@@H]3O)C4=CC=C(F)C=C4

-20°C

Ice Packs

Small Compound